CureVac (NASDAQ:CVAC)

PRESS RELEASE

published on 11/04/2024 at 13:03, 1 year 8 months ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
CureVac appoints Axel Sven Malkomes as CFO, bringing 30 years of industry experience. His role will drive strategic initiatives, financial foundation, and shareholder value

Biopharmaceutical Company CFO MRNA Technology CureVac Axel Sven Malkomes
PRESS RELEASE

published on 11/04/2024 at 13:00, 1 year 8 months ago

CureVac to Present at the 12th International mRNA Health Conference
CureVac to present new data at the 12th International mRNA Health Conference, showcasing developments in mRNA cancer vaccine and lipid nanoparticle delivery technology

Innovation Biopharmaceutical CureVac MRNA Platform MRNA Health Conference
BRIEF

published on 10/28/2024 at 13:05, 1 year 8 months ago

CureVac to Present New Findings at SITC Annual Meeting

Clinical Trials MRNA Technology Cancer Vaccine CureVac SITC Meeting
PRESS RELEASE

published on 10/28/2024 at 13:00, 1 year 8 months ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
CureVac to present at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, sharing immunogenicity data on mRNA-based cancer vaccine CVGBM. Conference details and contact info provided

CureVac MRNA Poster Presentation Immunogenicity Society For Immunotherapy Of Cancer
BRIEF

published on 09/13/2024 at 14:02, 1 year 10 months ago

CureVac's CVGBM Cancer Vaccine Shows Promising Results in Phase 1 Glioblastoma Study

CureVac Glioblastoma CVGBM Phase 1 Study T-cell Responses
PRESS RELEASE

published on 09/13/2024 at 13:57, 1 year 10 months ago

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
CureVac's CVGBM Cancer Vaccine induces promising immune responses in Phase 1 Study in Glioblastoma presented at ESMO 2024 Congress. Results show de novo T-cell activity & acceptable safety profile up to 100 µg dose

Cancer Vaccine CureVac CVGBM Phase 1 Study Immune Responses
BRIEF

published on 09/12/2024 at 13:02, 1 year 10 months ago

CureVac and GSK Report Positive Phase 2 Data for Influenza mRNA Vaccine

MRNA Technology Influenza Vaccine Phase 2 Results GSK Partnership CureVac Milestone
PRESS RELEASE

published on 09/12/2024 at 12:57, 1 year 10 months ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
CureVac Partner GSK reports positive Phase 2 results for seasonal influenza mRNA vaccine program. Data show immune responses to A and B strains with acceptable safety profile

GSK CureVac Phase 2 MRNA Vaccine Seasonal Influenza
BRIEF

published on 09/09/2024 at 13:05, 1 year 10 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Clinical Data CureVac MRNA Vaccine Glioblastoma ESMO Congress
PRESS RELEASE

published on 09/09/2024 at 13:00, 1 year 10 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
CureVac to present first CVGBM Glioblastoma cancer vaccine clinical data at ESMO 2024 Congress. First-in-human study results to be shared, highlighting mRNA technology's potential for cancer vaccines

MRNA Technology CureVac Glioblastoma CVGBM ESMO 2024 Congress

Published on 07/21/2026 at 23:00, 41 minutes ago

Viemed Healthcare Announces Second Quarter 2026 Earnings Conference Call Details
Published on 07/21/2026 at 22:30, 1 hour 11 minutes ago

Fermi Announces First Siemens Turbines Arrive at Port of Houston
Published on 07/21/2026 at 22:30, 1 hour 11 minutes ago

Matador Technologies Announces Management Transition
Published on 07/21/2026 at 22:15, 1 hour 26 minutes ago

Vanta Announces Updated Time for Participation in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22, 2026, at 12:00 p.m. ET
Published on 07/21/2026 at 22:00, 1 hour 41 minutes ago

Redwood AI Announces Closing of $3.5 Million Private Placement

View all ACCESSWIRE

Published on 07/21/2026 at 22:30, 1 hour 10 minutes ago

Strong second quarter: GEA raises full-year guidance for 2026
Published on 07/21/2026 at 22:16, 1 hour 24 minutes ago

EQS-Adhoc: GEA Group Aktiengesellschaft: Preliminary numbers for Q2 2026 exceed market expectation - increase of guidance for fiscal year 2026
Published on 07/21/2026 at 18:50, 4 hours 50 minutes ago

Soapeya, a DN Group AG Portfolio Company, Earns Top "Excellent" Rating from Dermatest and Proves Successful in Field Use in Ghana
Published on 07/21/2026 at 18:15, 5 hours 25 minutes ago

EuroTeleSites Reports Strong Q2/2026 Results with Growth Across Key Financial and Operating Metrics
Published on 07/21/2026 at 17:50, 5 hours 50 minutes ago

The New Measure of an EV Isn't Range, It's Peace of Mind

View all EQS

Published on 07/21/2026 at 18:41, 4 hours 59 minutes ago

ICADE - 2026 HY Financial Report
Published on 07/21/2026 at 18:13, 5 hours 27 minutes ago

ICADE – PR – 2026 HALF YEAR RESULTS
Published on 07/20/2026 at 18:20, 1 day 5 hours ago

Covivio - 2026 Half-year results: Earnings growth driven by active asset management
Published on 07/20/2026 at 18:04, 1 day 5 hours ago

Reporting on share buyback transactions carried out between July 8 and July 9, 2026
Published on 07/20/2026 at 17:45, 1 day 5 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News